Evidence map›Paper›PMID 36982571›Full record

ArticleInternational journal of molecular sciences2023

Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer.

Silvia Cantara, Cristina Dalmiglio, Carlotta Marzocchi, Alfonso Sagnella, Lucia Brilli, Andrea Trimarchi, Fabio Maino, Laura Valerio, Maria Grazia Castagna

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Silvia CantaraDepartment of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-5741-295X
Cristina DalmiglioDepartment of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
Carlotta MarzocchiDepartment of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-8573-4913
Alfonso SagnellaDepartment of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.ORCID 0000-0003-2247-9027
Lucia BrilliDepartment of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
Andrea TrimarchiDepartment of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.ORCID 0009-0000-4247-0869
Fabio MainoDepartment of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
Laura ValerioDepartment of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.ORCID 0000-0001-7723-7020
Maria Grazia CastagnaDepartment of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
University of Siena · IT

Funding

Ministry of Education, Universities and Research 20205HZBP8
6 · The paper itself

Abstract

Multi-kinase inhibitors (MKIs) represent the best therapeutic option in advanced thyroid cancer patients. The therapeutic efficacy and toxicity of MKIs are very heterogeneous and are difficult to predict before starting treatment. Moreover, due to the development of severe adverse events, it is necessary to interrupt the therapy some patients. Using a pharmacogenetic approach, we evaluated polymorphisms in genes coding for proteins involved with the absorption and elimination of the drug in 18 advanced thyroid cancer patients treated with lenvatinib, and correlated the genetic background with (1) diarrhea, nausea, vomiting and epigastric pain; (2) oral mucositis and xerostomia; (3) hypertension and proteinuria; (4) asthenia; (5) anorexia and weight loss; (6) hand foot syndrome. Analyzed variants belong to cytochrome P450 (

Indexed as

Antineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsHypertensionThyroid NeoplasmsCytochrome P-450 CYP3AGenotypeHumansIatrogenic DiseasePhenylurea CompoundsPilot ProjectsPolymorphism, Single NucleotideProtein Kinase InhibitorsQuinolinesAntineoplastic AgentsCytochrome P-450 CYP3AlenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesATP-binding cassette transporterscytochrome P450lenvatinibmulti-kinase inhibitorsSNPsthyroid cancer

Identifiers

PMID36982571
PMCPMC10049548
OpenAlexW4324148887

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read96
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.